These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1538891)

  • 1. [Epithelial ovarian cancer: a challenge in gynecologic oncology].
    Dauplat J; Piccart M
    Pathol Biol (Paris); 1992 Nov; 39(9):823-4. PubMed ID: 1538891
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose intensity regimens with epirubicin in ovarian cancer.
    Vermorken JB
    Pathol Biol (Paris); 1992 Nov; 39(9):833. PubMed ID: 1538894
    [No Abstract]   [Full Text] [Related]  

  • 3. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.
    Fanning J; Bennett TZ; Hilgers RD
    Obstet Gynecol; 1992 Dec; 80(6):954-60. PubMed ID: 1333066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapeutic treatment of advanced ovarian carcinoma. Preliminary results of the Piedmont-Liguria Cooperative Group].
    Conte PF; Rosso R; Bruzzone M; Sertoli MR; Rubagotti A; Santi L; Carnino F; Cottini M; Mossetti C; Gatti M
    Minerva Ginecol; 1984 Apr; 36(4):213-6. PubMed ID: 6547773
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.
    Edmonson JH; McCormack GW; Fleming TR; Cullinan SA; Krook JE; Malkasian GD; Podratz KC; Mailliard JA; Jefferies JA; Barlow JF
    Cancer Treat Rep; 1985 Nov; 69(11):1243-8. PubMed ID: 3937598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
    Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the efficacy of cisplatin-based chemotherapy in epithelial ovarian cancer; comparison with treatments employed before the cisplatin era].
    Kamura T; Tsukamoto N; Suenaga T; Kaku T; Matsukuma K; Matsuyama T
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1260-3. PubMed ID: 3579324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of chemotherapy for ovarian carcinoma.
    ten Bokkel Huinink WW
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):583-5. PubMed ID: 3133217
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The potentials of combined chemotherapy in disseminated ovarian cancer].
    Gorbunova VA; Perevodchikova NI; Kozachenko VP; Ryzhakov VM; Marenich AF; Zhordania KI
    Akush Ginekol (Mosk); 1991 Feb; (2):54-7. PubMed ID: 1907433
    [No Abstract]   [Full Text] [Related]  

  • 15. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors: cisplatin regimens for patients with ovarian cancer after failure of chemotherapy.
    Bruckner HW; Cohen CJ; Feuer E; Wallach RC; Kabakow B; Holland JF
    Obstet Gynecol; 1987 Jan; 69(1):114-20. PubMed ID: 3099235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and prognostic features of advanced ovarian carcinoma.
    Lund B
    Dan Med Bull; 1993 Nov; 40(5):537-45. PubMed ID: 8299398
    [No Abstract]   [Full Text] [Related]  

  • 19. [Choice of first-line chemotherapy for advanced ovarian cancer].
    Tiuliandin SA
    Vopr Onkol; 1999; 45(4):350-4. PubMed ID: 10532090
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term survival of patients with advanced ovarian carcinoma treated with cisplatin-based chemotherapy regimens.
    De Pree N; Wils J
    Anticancer Res; 1989; 9(6):1869-71. PubMed ID: 2697190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.